2.00

4.76% -0.10

Allogene Therapeutics Inc (ALLO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$2.10

Aprire:

$2.1

Volume 24 ore:

7.76M

Relative Volume:

0.68

Capitalizzazione di mercato:

$690.31M

Reddito:

$22,000

Utile/perdita netta:

$-173.76M

Rapporto P/E:

-2.6038

EPS:

-0.7681

Flusso di cassa netto:

$-109.53M

1 W Prestazione:

-3.85%

1M Prestazione:

+12.36%

6M Prestazione:

+16.96%

1 anno Prestazione:

+58.73%

Intervallo 1D:

$1.94

$2.10

Intervallo di 1 settimana:

$1.94

$2.185

Portata 52W:

$0.9842

$4.46

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Nome

Allogene Therapeutics Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

(650) 457-2700

Indirizzo

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Dipendente

152

Cinguettio

@AllogeneTx

Prossima data di guadagno

2026-08-12

Ultimi documenti SEC

ALLO's Discussions on Twitter

Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALLO Allogene Therapeutics Inc	2.00	690.31M	22,000	-173.76M	-109.53M	-0.7681
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-16	Aggiornamento	JP Morgan	Underweight → Neutral
2026-04-10	Ripresa	Jefferies	Buy
2026-01-09	Aggiornamento	Citizens JMP	Mkt Perform → Mkt Outperform
2025-10-10	Downgrade	JP Morgan	Neutral → Underweight
2025-05-14	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
2025-03-14	Aggiornamento	Citizens JMP	Mkt Perform → Mkt Outperform
2024-08-08	Ripresa	Oppenheimer	Outperform
2024-05-31	Iniziato	Piper Sandler	Overweight
2024-01-05	Downgrade	Guggenheim	Buy → Neutral
2024-01-05	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-08	Iniziato	Citigroup	Buy
2023-06-26	Ripresa	Oppenheimer	Outperform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-01-24	Aggiornamento	JP Morgan	Neutral → Overweight
2023-01-06	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-12-12	Downgrade	BofA Securities	Buy → Underperform
2022-08-10	Downgrade	Raymond James	Outperform → Mkt Perform
2022-07-15	Aggiornamento	Goldman	Neutral → Buy
2022-06-03	Iniziato	Robert W. Baird	Neutral
2022-02-28	Reiterato	B. Riley Securities	Buy
2021-10-20	Iniziato	Cowen	Outperform
2021-10-08	Downgrade	Goldman	Buy → Neutral
2021-10-08	Downgrade	Stifel	Buy → Hold
2021-09-23	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-21	Ripresa	Jefferies	Buy
2021-05-20	Aggiornamento	Truist	Hold → Buy
2021-05-14	Iniziato	B. Riley Securities	Buy
2021-01-26	Aggiornamento	Stifel	Hold → Buy
2020-12-10	Ripresa	H.C. Wainwright	Buy
2020-11-24	Iniziato	BofA Securities	Buy
2020-10-23	Iniziato	RBC Capital Mkts	Outperform
2020-06-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-05-29	Reiterato	H.C. Wainwright	Buy
2020-05-19	Aggiornamento	ROTH Capital	Neutral → Buy
2020-05-15	Aggiornamento	Guggenheim	Neutral → Buy
2020-05-14	Reiterato	H.C. Wainwright	Buy
2020-05-14	Downgrade	SunTrust	Buy → Hold
2020-04-13	Iniziato	SunTrust	Buy
2020-03-13	Iniziato	H.C. Wainwright	Buy
2020-03-05	Iniziato	Stifel	Hold
2020-02-24	Iniziato	Berenberg	Hold
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-11-04	Iniziato	Canaccord Genuity	Buy
2019-08-09	Iniziato	BTIG Research	Buy
2019-06-05	Iniziato	ROTH Capital	Neutral
2019-05-31	Iniziato	Guggenheim	Neutral
2019-05-23	Iniziato	Stifel	Hold
2019-03-29	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie

Jul 11, 2026

Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN

Jul 11, 2026

Jul 09, 2026

Cancer cell therapy pioneer Allogene’s new CEO is talking about a new revolution - The Business Journals

Jul 09, 2026

Jul 06, 2026

Form 4 Allogene Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada

Jul 06, 2026

Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs - Stock Titan

Jul 06, 2026

Jul 05, 2026

ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits

Jul 05, 2026

Jul 04, 2026

Allogene Therapeutics shows promise with ALPHA3 trial and ALLO-329, cutting losses and extending cash runway. - Pluang

Jul 04, 2026

Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO) - Seeking Alpha

Jul 04, 2026

Jul 02, 2026

ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill

Jul 02, 2026

Jun 30, 2026

Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.com - Investing.com Nigeria

Jun 30, 2026

Jun 28, 2026

Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 28, 2026

Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Yahoo Finance

Jun 28, 2026

Jun 27, 2026

Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 27, 2026

Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Price to book forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 27, 2026

Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 26, 2026

Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO) - TradingView

Jun 26, 2026

Jun 25, 2026

Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN

Jun 25, 2026

ALLO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations - Traders Union

Jun 25, 2026

Allogene Therapeutics (ALLO) Edges Higher Near Key Resistance LevelInsider Selling Alerts - dars.gov.et

Jun 25, 2026

Jun 24, 2026

Recent pharma exec shake-ups signal strategic shifts - Pharma Voice

Jun 24, 2026

Jun 23, 2026

Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria

Jun 23, 2026

Allogene (ALLO) director Kazam converts 47,700 RSUs and receives 95,400-unit equity grant - Stock Titan

Jun 23, 2026

Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs - Stock Titan

Jun 23, 2026

Allogene Therapeutics (ALLO) director receives 144,400 stock options grant - Stock Titan

Jun 23, 2026

Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award - Stock Titan

Jun 23, 2026

Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery - Stock Titan

Jun 23, 2026

[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 23, 2026

Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery - Stock Titan

Jun 23, 2026

Jun 22, 2026

Form 424B5 Allogene Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026

Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan - Stock Titan

Jun 22, 2026

Allogene (NASDAQ: ALLO) launches $135M ATM program with TD Cowen at $2.00 ref - Stock Titan

Jun 22, 2026

Jun 19, 2026

Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News

Jun 19, 2026

Jun 18, 2026

ALLO: All proposals, including director elections and share increase, were approved without contest - TradingView

Jun 18, 2026

ALLO: All proposals passed, including director elections and share authorization increase - TradingView

Jun 18, 2026